Venture Investors

Akebia Therapeutics is a pharmaceutical company focusing on treatments for ischemia and improvement of vascular disease. The company has in-licensed high-quality drug development programs and treatment assets from Procter & Gamble.

Celleration is developing novel technologies for the therapeutic treatment of chronic wounds. Their core technology is a patented non-imaging, non-contact ultrasound system called Mist Ultra Sound Transport that significantly speeds the healing of chronic wounds.

Deltanoid Pharmaceuticals is a biopharmaceutical company engaged in the research, development and commercialization of novel vitamin D therapies for the treatment of human diseases.

Euthymics Bioscience is a neuroscience focused biopharmaceutical company developing novel therapeutics for Major Depressive Disorder (MDD) and Attention Deficit/Hyperactivity Disorder (ADHD).

Gala Biotech (Acquired by Cardinal Health – (NYSE: CAH)) developed an innovative portfolio of proprietary protein expression technologies in mammalian cells. These systems have applications ranging from early development protein screening to large-scale pharmaceutical manufacturing.

HistoSonics is a medical device company that is developing Histotripsy, a non-invasive image guided and robotic tissue ablation technology that was licensed from the University of Michigan. Histotripsy is a versatile platform that will replace traditional surgical and minimally invasive methods to reduce patient trauma and health care costs.

IntraLase (NASDAQ: ILSE) was aquired by Advanced Medical Optics (NYSE: EYE). IntraLase is a medical devices company that developed an automated procedure for laser vision correction. The “IntraLasik” procedure was the industry’s first all laser surgery.

Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen’s lead product is a vaccine to protect against dengue fever, a disease that threatens 3.6 billion people across the globe.

LenSx Lasers (Acquired by Alcon, Inc. (NYSE: ACL)) is developing breakthrough, image-guided femtosecond laser technology that will transform today’s cataract surgery from a very manual, multi-step procedure to that of a very precise, more automated all-laser procedure.

Mithridion is a biopharmaceutical company that discovers and develops drugs for neurodegenerative diseases, with a focus on Alzheimer’s disease.

NanoBio is a biopharmaceutical company developing and commercializing topical anti-infective products and vaccines based on their proprietary nanoemulsion technology for the prevention and treatment of infectious diseases.

Nerites (Acquired by Kensey Nash, Corp. (NASDAQ:  KNSY)) is a biopharmaceutical developing a new generation of synthetic coating and surgical adhesive biomaterials that can enhance natural tissue repair, reduce complications from traditional devices and degrade safely when they are no longer needed.

NeuWave Medical is a University of Wisconsin-Madison start-up that develops minimally invasive technologies for the treatment of cancer. Their core technology is a proprietary microwave ablation system that provides substantial benefits over traditional thermal ablation techniques.

NimbleGen Systems (Acquired by Roche (NASDAQ: RHHBY)) is the leading supplier of customized high-density microarray products and services, offering unprecedented flexibility for genomics research.

Novelos, formerly Cellectar, is a radiopharmaceuticals company that designs, develops and manufactures products to detect, treat and monitor a wide variety of human cancers. Their proprietary product candidates combine lipid-like molecules, phospholipid ethers (PLEs), with radioisotopes that destroy malignant cells.

Procertus is an oncology-based pharmaceutical company whose primary mission is to protect cancer patients against the side effects of chemotherapy and radiotherapy.

Promega is a worldwide leader in applying biochemistry and molecular biology to the development of innovative, high-value biological reagents and systems for the life sciences industry.

Third Wave Technologies (NASDAQ: TWTI) was aquired by Hologic (Nasdaq: HOLX). The Company is a leader in the development and marketing of molecular diagnostics for a variety of DNA and RNA analysis applications, providing physicians and researchers with superior tools to diagnose and treat disease.

Tissue Regeneration Systems (TRS) is a spin-out of the Universities of Michigan and Wisconsin, developing bioactive medical devices for bone and soft tissue regeneration. TRS’ first products are in the spine and craniofacial markets.

TomoTherapy (Nasdaq: TOMO) develops, manufactures and markets a leading system for precision delivery of radiation therapy to cancer patients. Their Hi·Art System® integrates treatment planning, patient positioning and treatment delivery in one system.

ZyStor Therapeutics (Acquired by BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN)) is a biotechnology company developing novel therapeutics, with the potential to significantly improve the lives of patients who suffer from genetic disorders known as lysosomal storage diseases (LSDs).